Biodesix is a data-driven diagnostic solutions company utilizing technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, Co. provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. Co.'s diagnostic blood-based tests across the lung cancer continuum of care include: Nodify XL2® and Nodify CDT® tests, which assess the risk of lung cancer to help identify the appropriate treatment pathway. The BDSX average annual return since 2020 is shown above.
The Average Annual Return on the BDSX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BDSX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BDSX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|